The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy. (26th November 2021)

• Record Type: Journal Article
• Authors: Aktepe, Oktay Halit; Guven, Deniz Can; Sahin, Taha Koray; Yildirim, Hasan Cagri; Celikten, Burcu; Yeter, Haci Hasan; Yuce, Deniz; Dizdar, Omer; Erman, Mustafa
• Is Part Of: Nutrition and cancer. Volume 73:Number 10(2021)
• Page Start: 1957
• Page End: 1963
• Publication Date: 2021-11-26
• Subjects: Cancer -- Periodicals; Nutrition -- Periodicals; Cancer; Nutrition; Periodicals; 616.9940654
• DOI: 10.1080/01635581.2021.1871925
• Languages: English
• ISSNs: 0163-5581

Abstract

Abstract: Background: We aimed to investigate the prognostic value of red cell distribution width (RDW) in metastatic renal cell carcinoma (mRCC) patients treated with targeted therapy, including sunitinib and pazopanib. Methods: A total of 104 mRCC patients were included. The Kaplan–Meier method was used to estimate overall survival (OS) and progression-free survival (PFS), and the long-rank test was used for comparison. Univariate and multivariate Cox proportional hazards models were used to determine the association between RDW and PFS and OS. Results: The PFS and OS of all cohorts were 11.8 mo and 25.9 mo, respectively. Receiver operating characteristic analysis revealed that RDW level ≥15.4 was the optimal cutoff value for OS prediction with 73.53% sensitivity and 61.11% specificity (area under curve: 0.64, P = 0.012). RDW level ≥15.4 was found as an independent prognostic parameter for OS when adjusted for the number of covariates, including the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) scoring system (hazard ratio: 1.125, 95% confidence interval: 1.024–2.235, P = 0.014). Conclusions: Our study revealed that high RDW level, a routinely and easily assessed marker, was significantly associated with worse survival outcomes in mRCC patients treated with targeted therapy.